JD Health International, Inc. (HK:6618)
:6618
Want to see HK:6618 full AI Analyst Report?
6618 Stock Chart & Stats
HK$60.30
HK$0.45(1.61%)
At close: 4:00 PM EST
HK$60.30
HK$0.45(1.61%)
Day’s Range― - ―
52-Week RangeHK$38.30 - HK$71.70
Previous CloseN/A
Volume5.25M
Average Volume (3M)7.60M
Market Cap
HK$129.65B
Enterprise ValueHK$81.27B
Total Cash (Recent Filing)HK$47.00B
Total Debt (Recent Filing)HK$636.29M
Price to Earnings (P/E)29.7
Beta1.39
Next Earnings
Aug 13, 2026EPS Estimate
1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding3,210,775,100
10 Day Avg. Volume6,883,323
30 Day Avg. Volume7,596,953
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)2.65
Price to Sales (P/S)2.17
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$72.11Price Target Upside19.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)1.86
Revenue Forecast (FY)HK$86.72B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExceptionally low leverage and meaningful equity growth provide durable financial flexibility. This conservative capital structure supports continued investment in supply chain, AI and offline rollouts, reduces bankruptcy risk, and preserves optionality to fund growth or absorb shocks without relying on volatile external financing.
Robust Revenue And User GrowthSustained double-digit revenue growth and sizable net adds (220M annual active users, +34M) indicate durable market traction and network effects. High top-line momentum across quarters supports scalable unit economics and platform leverage across e-commerce, services and insurance over the medium term.
Product Launch And Go-to-market ScaleRapid expansion of drug launches and strong launch execution demonstrate durable commercial capabilities and supplier relationships. The ability to scale product introductions and capture launch demand supports long-term revenue diversification, strengthens supplier ties, and enhances competitive positioning in pharmacy retail.
Bears Say
Free-cash-flow ResetA 2025 FCF reset to zero signals a structural shift in cash conversion driven by higher investment or working-capital needs. That reduces near-term financial flexibility for buybacks, dividends or opportunistic M&A and raises reliance on operating cash or parent support while investments mature.
Revenue Concentration In Direct SalesHeavy reliance on direct-sales (83% of revenue) concentrates execution and supplier risks. Adverse pricing, reimbursement changes, or supplier disruptions in those categories could materially affect margins and growth, limiting diversification benefits from service revenue despite service growth.
AI Monetization UncertaintyHigh engagement with AI products but unclear commercialization paths means multi-year upside is uncertain. Continued investment without clear monetization could compress margins and cash conversion; durable value depends on converting usage into sustainable B2B or B2C revenue streams.
JD Health International, Inc. News
6618 FAQ
What was JD Health International, Inc.’s price range in the past 12 months?
JD Health International, Inc. lowest stock price was HK$38.30 and its highest was HK$71.70 in the past 12 months.
What is JD Health International, Inc.’s market cap?
JD Health International, Inc.’s market cap is HK$129.65B.
When is JD Health International, Inc.’s upcoming earnings report date?
JD Health International, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 84 days.
How were JD Health International, Inc.’s earnings last quarter?
JD Health International, Inc. released its earnings results on Mar 05, 2026. The company reported HK$1.077 earnings per share for the quarter, beating the consensus estimate of HK$0.748 by HK$0.328.
Is JD Health International, Inc. overvalued?
According to Wall Street analysts JD Health International, Inc.’s price is currently Undervalued.
Does JD Health International, Inc. pay dividends?
JD Health International, Inc. does not currently pay dividends.
What is JD Health International, Inc.’s EPS estimate?
JD Health International, Inc.’s EPS estimate is 1.35.
How many shares outstanding does JD Health International, Inc. have?
JD Health International, Inc. has 3,210,775,100 shares outstanding.
What happened to JD Health International, Inc.’s price movement after its last earnings report?
JD Health International, Inc. reported an EPS of HK$1.077 in its last earnings report, beating expectations of HK$0.748. Following the earnings report the stock price went down -6.219%.
Which hedge fund is a major shareholder of JD Health International, Inc.?
Currently, no hedge funds are holding shares in HK:6618
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JD Health International, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$72.11 (19.59% Upside)
HK$72.11 (19.59% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
130.47%
12-Months-Change
Fundamentals
Return on Equity
9.03%
Trailing 12-Months
Asset Growth
19.80%
Trailing 12-Months
Company Description
JD Health International, Inc.
JD Health International Inc., an investment holding company, operates an online healthcare platform in the People's Republic of China. It offers pharmaceutical and healthcare products, including OTC drugs, prescription drugs, and medical devices and supplies, as well as health supplements and tonics through direct selling and an online retail pharmacy network. The company also provides online healthcare services, online consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services; health management and intelligent healthcare solutions, as well as technical and advertising services. In addition, it offers access to medical checkups, medical aesthetics, vaccination appointments, dental care services, and nucleic acid testing tests. The company was incorporated in 2018 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
6618 Stock 12 Month Forecast
Average Price Target
HK$72.11
▲(19.59% Upside)
Technical Analysis
Rici Healthcare Holdings Ltd.
―
Jinxin Fertility Group Ltd.
―
Gushengtang Holdings Limited
―
Guangdong Kanghua Healthcare Co., Ltd. Class H
―
Hygeia Healthcare Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---